DA
LLY icon

Dillon & Associates’s Eli Lilly LLY Stock Holding History

Dillon & Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5M Buy
12,093
+3,142
+35% +$3.21M 1.77% 18
2026
Q1 		$8.23M Buy
8,951
+1,840
+26% +$1.87M 1.13% 23
2025
Q4 		$7.64M Buy
7,111
+1,138
+19% +$1.09M 0.99% 26
2025
Q3 		$4.56M Buy
5,973
+1,745
+41% +$1.3M 0.59% 35
2025
Q2 		$3.3M Buy
4,228
+1,706
+68% +$1.33M 0.45% 38
2025
Q1 		$2.08M Buy
2,522
+1,276
+102% +$1.06M 0.31% 44
2024
Q4 		$962K Buy
1,246
+794
+176% +$657K 0.13% 56
2024
Q3 		$400K Hold
452
– – 0.06% 66
2024
Q2 		$409K Hold
452
– – 0.06% 67
2024
Q1 		$352K Hold
452
– – 0.06% 69
2023
Q4 		$264K Sell
452
-19
-4% -$11.1K 0.05% 73
2023
Q3 		$253K Buy
471
+20
+4% +$10.3K 0.05% 72
2023
Q2 		$212K Buy
+451
New +$189K 0.04% 77

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dillon & Associates's LLY Position: Q2 2026 in Review

Dillon & Associates increased its Eli Lilly (LLY) stake by 35% in Q2 2026, buying an estimated $3.21M and bringing the position to 12,093 shares worth $14.5M. The position accounts for 1.77% of the portfolio, ranked #18.

Dillon & Associates first reported a position in LLY in Q2 2023 and has held it in 13 quarters since. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Dillon & Associates held 12,093 shares of Eli Lilly worth $14.5M as of Q2 2026.
  • Dillon & Associates bought 3,142 Eli Lilly shares in Q2 2026, an estimated $3.21M.
  • Eli Lilly made up 1.77% of Dillon & Associates's portfolio in Q2 2026, its #18 holding.
  • Dillon & Associates first reported a position in Eli Lilly in Q2 2023 and has held it in 13 quarters since.
  • 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Dillon & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.